At 7.2% CAGR, the South & Central America Home Infusion Therapy Market is projected to be worth US$ 2,587.96 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the South & Central America home infusion therapy market was valued at US$ 1,704.27 million in 2022 and is expected to reach US$ 2,587.96 million by 2028, registering a CAGR of 7.2% from 2022 to 2028. Reduction in duration of hospital stays and cost of care and increasing incidences of chronic disorders coupled with rising geriatric population are the critical factors attributed to the South & Central America home infusion therapy market expansion.  

Developing countries report a high prevalence of chronic diseases due to significant shifts in people’s lifestyles. Leading pharmaceutical companies have been focusing on increasing their reach across emerging markets by expanding their distribution networks and augmented manufacturing capabilities. Developing economies offer potential growth opportunities to infusion therapy device manufacturers. This can be attributed to the large patient population, high CVD prevalence, and improving healthcare infrastructure.

In developing countries, the number of patients receiving home infusion therapy has been limited in the past. Even though hospitals have rapidly adopted smart infusion pumps integrated with features such as electronic health records (EHR) integration and medication safety software, the majority of home infusion service providers continue to use traditional pumps. However, developing countries are focused on improving their healthcare infrastructure and services, which is encouraging the healthcare sector to upgrade these products and services. Moreover, significant investments in research and development play a key role in the technological upgrade of products and services in emerging countries. With the increasing availability of such upgraded medical offerings, their use is likely to rise in these countries in the future.

Due to the COVID-19 pandemic, hospitals were under huge pressure to cater to a vast number of patients, which resulted in overpopulated emergency rooms (ERs), and overwhelmed doctors and medical staff; therefore, the healthcare sectors in developing countries witnessed a crucial shift to homecare settings. Additionally, many patients withdrew from treatments within hospital settings due to the fear of contracting COVID-19, making home care a good option. In addition, patients were prone to hospital-acquired infections or healthcare-associated infections (HAIs) while receiving services in hospitals or other healthcare facilities. With high morbidity and mortality rates, HAIs cost healthcare systems billions of dollars annually. With growing infection rates, there is an increased focus on reducing the incidence of HAIs, owing to the huge costs associated with treating these infections that exert additional economic burdens on the healthcare system. Thus, due to COVID-19 pandemic, home infusion is perceived as an effective treatment option to reduce the risk of getting the HAIs, which serves as a significant opportunity for the home infusion therapy market.   

On the contrary, recalls of infusion pumps and safety concerns associated with home infusion hurdles the growth of South & Central America home infusion therapy market.

Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The home infusion therapy market segment is sub segmented into insulin pumps, elastomeric pumps, syringe pumps, and others. The infusion pumps segment held 55.3% market share in 2022, amassing US$ 941.71 million. It is projected to garner US$ 1,449.63 million by 2028 to expand at 7.8% CAGR during 2022–2028.   

Based on application, the home infusion therapy market is segmented into enteral nutrition, anti-infective, endocrinology, hydration therapy, chemotherapy, specialty pharmaceuticals, and others. The anti-infective segment held 25.0% market share in 2022, amassing US$ 426.58 million. It is projected to garner US$ 652.39 million by 2028 to expand at 7.3% CAGR during 2022–2028.    

Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural. The intramuscular segment held 75.8% market share in 2022, amassing US$ 1,292.45 million. It is projected to garner US$ 1,977.05 million by 2028 to expand at 7.3% CAGR during 2022–2028.    

Based on country, the South & Central America home infusion therapy market is segmented into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that the Rest of South & Central America captured 38.0% market share in 2022. It was assessed at US$ 648.14 million in 2022 and is likely to hit US$ 965.57 million by 2028, exhibiting a CAGR of 6.9% during the forecast period.  

Key players dominating the South & Central America home infusion therapy market are B. Braun Melsungen AG; Baxter International Inc; Nipro Corp; Becton Dickinson and Co; Fresenius Kabi AG; ICU Medical Inc; Terumo Corp, among others.         

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com